Meta Description: The global Protein Sequencing Market size is projected to grow from USD 2.39 billion in 2026 to USD 3.45 billion by 2034, at a CAGR of 4.72%. Explore market trends, key segments, regional outlook, and leading players.
The global Protein Sequencing Market is on a robust growth trajectory, driven by cutting-edge advancements in analytical technologies and an accelerating demand for detailed protein analysis across pharmaceutical, biotechnology, and academic sectors. According to a comprehensive report published by Fortune Business Insights, the Protein Sequencing Market was valued at USD 2.29 billion in 2025 and is projected to grow from USD 2.39 billion in 2026 to USD 3.45 billion by 2034, exhibiting a steady CAGR of 4.72% during the forecast period.
This protein sequencing market growth forecast highlights a decade of continued momentum fuelled by personalized medicine, proteomics research, and the global push to understand disease at the molecular level. As protein sequencing market share continues to expand, businesses, researchers, and investors are paying close attention to where this market is heading.
One of the most powerful protein sequencing market drivers is the surging demand for protein therapeutics. The increasing global burden of chronic diseases — including cancer, cardiovascular disorders, and genetic conditions — is compelling pharma and biotech companies to invest heavily in protein-based drug development. In June 2025, CSL received U.S. FDA approval for ANDEMBRY, a first-of-its-kind treatment targeting factor XIIa for hereditary angioedema (HAE), underlining how protein sequencing is directly enabling life-saving drug approvals.
These developments underscore why the protein sequencing market size is set to grow — as more biologics, monoclonal antibodies, fusion proteins, and biosimilars reach clinical pipelines, the need for precise protein structural analysis becomes non-negotiable.
Rising funding activities are creating lucrative opportunities in the protein sequencing market. In July 2025, Portal Biotech raised USD 32.4 million in a Series A round to advance nanopore-based protein sequencing at the single-molecule level. Similarly, the University of Oulu received USD 3.25 million from the European Innovation Council (EIC) in October 2025 to develop novel optical protein sequencing technology. These investments reflect the global scientific community's commitment to next-generation sequencing capabilities and are directly fuelling protein sequencing market growth.
Automation and AI integration are emerging as key protein sequencing market trends. Automated platforms minimize manual errors, improve throughput, and accelerate complex sequencing workflows. In June 2025, Ainnocence launched the BioSynthAI platform, leveraging cutting-edge AI algorithms to optimize protein and enzyme activity through in-silico design — an innovation accelerating biopharmaceuticals and sustainable biotech.
Despite strong growth drivers, the protein sequencing market faces notable headwinds:
The market is segmented into Instruments, Reagents & Consumables, and Software & Services. In 2025, the reagents & consumables segment dominated, driven by their continuous requirement in proteomics research and drug development pipelines. A notable catalyst was the September 2025 launch of Quantum-Si's V4 Sequencing Kit, compatible with both Platinum and Platinum Pro instruments. The instruments segment is projected to grow at a CAGR of 3.96% over the forecast period.
Technology segments include Mass Spectrometry, Edman Degradation, Next-Generation Sequencing (NGS), and Others. Mass spectrometry led with an overwhelming 80.8% market share in 2025, thanks to its unmatched sensitivity, accuracy, and throughput in identifying thousands of proteins in a single run. In May 2025, Bruker Corporation launched the timsOmni system, a new timsTOF-based mass spectrometer for drug discovery and clinical applications. Meanwhile, the next-generation sequencing (NGS) segment is the fastest-growing, expected to surge at a CAGR of 12.34% — making NGS the most exciting frontier in the protein sequencing market growth story.
Applications span biotherapeutics & biologics characterization, proteomics & biomarker discovery, drug discovery & target validation, genetic engineering & synthetic biology, and others. The biotherapeutics & biologics characterization segment held a 44.7% share in 2025, supported by pharma and biotech companies' relentless focus on complex biologics analysis. In September 2025, Illumina Inc. launched Illumina Protein Prep for NGS-based proteomics discovery, targeting cancer, cardio-metabolic, and immunologic research. The proteomics & biomarker discovery segment is set to grow at a CAGR of 5.53% through the forecast period.
End users include Pharmaceutical & Biotechnology Companies, CROs & CDMOs, Academic & Research Institutes, and Others. Pharma and biotech companies dominated with a 49.8% share in 2025, underpinned by robust development pipelines and clinical facilities. A landmark example: in June 2025, BioNTech SE and Bristol Myers Squibb partnered to co-develop BioNTech's investigational bispecific antibody BNT327 for multiple solid tumor indications. The CROs & CDMOs segment is projected to grow at a CAGR of 5.10%.
North America dominated the protein sequencing market share with 41.48% in 2025, valued at USD 0.95 billion. The U.S. alone contributed USD 0.88 billion, supported by synthetic biology infrastructure, established players, and a thriving start-up ecosystem. In October 2025, Waters Corporation unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), targeting next-generation therapeutics and structural biology.
Europe recorded USD 0.62 billion in 2025 and is growing at 3.91% CAGR. Germany led at USD 0.15 billion, followed by the U.K. at USD 0.13 billion and France at USD 0.12 billion, driven by active R&D and proteomics research.
Asia Pacific is estimated at USD 0.55 billion in 2025, with India and China contributing USD 0.18 billion and USD 0.07 billion respectively. Rapidly scaling research infrastructure and cost-efficient manufacturing position APAC as a high-opportunity region for protein sequencing market players.
Latin America recorded USD 0.10 billion in 2025, with growing interest from global players. The GCC region in Middle East & Africa reached USD 0.04 billion, with moderate growth expected over the forecast period.
The Protein Sequencing Market is semi-fragmented, with major players including:
Key recent developments include:
| Parameter | Details |
|---|---|
| Market Value (2025) | USD 2.29 Billion |
| Market Value (2026) | USD 2.39 Billion |
| Market Value (2034) | USD 3.45 Billion |
| CAGR (2026–2034) | 4.72% |
| Leading Region | North America (41.48% share) |
| Fastest Technology | Next-Generation Sequencing (12.34% CAGR) |
| Leading Technology | Mass Spectrometry (80.8% share) |
| Leading Application | Biotherapeutics & Biologics (44.7% share) |
| Leading End User | Pharma & Biotech (49.8% share) |
The global protein sequencing market stands at the intersection of biological science, advanced technology, and high-growth healthcare demand. With the market expanding from USD 2.39 billion in 2026 to USD 3.45 billion by 2034 at a CAGR of 4.72%, stakeholders across pharma, biotech, and research sectors must act strategically. The surging protein sequencing market size, evolving protein sequencing market share dynamics, rising proteomics investments, and rapid AI-powered automation are collectively shaping a future where protein sequencing is central to modern medicine and drug discovery.
For the complete Protein Sequencing Market Size, Share & Growth Forecast 2032 report and detailed segmentation data, access the full research at Fortune Business Insights: 👉 Protein Sequencing Market Report – Fortune Business Insights
Source: Fortune Business Insights – Protein Sequencing Market Size, Share & Industry Analysis, 2026–2034